267 related articles for article (PubMed ID: 26122369)
1. Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Multimodality Therapy.
Evans DB; George B; Tsai S
Ann Surg Oncol; 2015 Oct; 22(11):3409-13. PubMed ID: 26122369
[No Abstract] [Full Text] [Related]
2. How to define and manage borderline resectable pancreatic cancer.
Papavasiliou P; Chun YS; Hoffman JP
Surg Clin North Am; 2013 Jun; 93(3):663-74. PubMed ID: 23632151
[TBL] [Abstract][Full Text] [Related]
3. [Neoadjuvant therapy vs. upfront resection for resectable pancreatic cancer].
Strobel O; Büchler MW
Chirurg; 2017 Jul; 88(7):619. PubMed ID: 28573533
[No Abstract] [Full Text] [Related]
4. Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma.
Schwarz L; Katz MH
Hematol Oncol Clin North Am; 2015 Aug; 29(4):727-40. PubMed ID: 26226907
[TBL] [Abstract][Full Text] [Related]
5. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
Kwon D; McFarland K; Velanovich V; Martin RC
Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
[TBL] [Abstract][Full Text] [Related]
6. Active Systemic Treatment of Pancreatic Cancer.
Tempero M
J Natl Compr Canc Netw; 2017 May; 15(5S):723-725. PubMed ID: 28515255
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Advances in Localized Pancreatic Cancer.
Tsai S; Evans DB
JAMA Surg; 2016 Sep; 151(9):862-8. PubMed ID: 27276001
[TBL] [Abstract][Full Text] [Related]
8. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
Loehrer AP; Ferrone CR
Dig Surg; 2016; 33(4):343-50. PubMed ID: 27216011
[TBL] [Abstract][Full Text] [Related]
10. Multimodality management of borderline resectable pancreatic adenocarcinoma.
Prakash LR; Katz MHG
Chin Clin Oncol; 2017 Jun; 6(3):27. PubMed ID: 28705004
[TBL] [Abstract][Full Text] [Related]
11. Borderline resectable pancreatic cancer: definitions and the importance of multimodality therapy.
Evans DB; Erickson BA; Ritch P
Ann Surg Oncol; 2010 Nov; 17(11):2803-5. PubMed ID: 20737218
[No Abstract] [Full Text] [Related]
12. Neoadjuvant chemoradiotherapy for locally advanced pancreas cancer rarely leads to radiological evidence of tumour regression.
Dudeja V; Greeno EW; Walker SP; Jensen EH
HPB (Oxford); 2013 Sep; 15(9):661-7. PubMed ID: 23458352
[TBL] [Abstract][Full Text] [Related]
13. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
[TBL] [Abstract][Full Text] [Related]
14. Management of borderline and locally advanced pancreatic cancer: where do we stand?
He J; Page AJ; Weiss M; Wolfgang CL; Herman JM; Pawlik TM
World J Gastroenterol; 2014 Mar; 20(9):2255-66. PubMed ID: 24605025
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Histological Basis of Adenosquamous Carcinoma of the Pancreas: A 30-year Experience.
Moslim MA; Lefton MD; Ross EA; Mackrides N; Reddy SS
J Surg Res; 2021 Mar; 259():350-356. PubMed ID: 33190924
[TBL] [Abstract][Full Text] [Related]
16. New developments in the management of borderline resectable pancreatic cancer.
Sharma J; Ng J; Goodman MD; Saif MW
JOP; 2013 Mar; 14(2):123-5. PubMed ID: 23474551
[TBL] [Abstract][Full Text] [Related]
17. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
18. Management of Borderline Resectable Pancreatic Cancer.
Toesca DAS; Koong AJ; Poultsides GA; Visser BC; Haraldsdottir S; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1155-1174. PubMed ID: 29722658
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Therapy: When Should It Be Used for Pancreatic Cancer?
Kelly KN; Macedo FI; Merchant NB
Adv Surg; 2020 Sep; 54():49-68. PubMed ID: 32713439
[No Abstract] [Full Text] [Related]
20. Neoadjuvant therapy for resectable pancreatic cancer.
Raut CP; Evans DB; Crane CH; Pisters PW; Wolff RA
Surg Oncol Clin N Am; 2004 Oct; 13(4):639-61, ix. PubMed ID: 15350939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
